Press release
Polycythemia Vera Market Size in the 7MM was ~USD 2,000 Million in 2025 and It is Expected to Grow at a Significant CAGR of 8.9% to Reach ~USD 5,600 Million by 2036, Estimates DelveInsight
Discover Key Insights into the Polycythemia Vera Market with DelveInsight's In-Depth Report @ Polycythemia Vera Market Size-
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Polycythemia Vera Market Report
• In June 2026, Deciphera Pharmaceuticals dosed the first patient in its global Phase 3 INTREPID trial evaluating sapablursen, an investigational RNAi therapeutic targeting the TMPRSS6 gene.
• In June 2026, PharmaEssentia USA Corporation announced the U.S. FDA approval and commercial launch of the BESREMi Pen (ropeginterferon alfa-2b-njft), a pre-filled subcutaneous injection device designed to streamline self-administration.
• In May 2026, the U.S. FDA approved Incyte's Jakafi XR (ruxolitinib extended-release) tablets, indicated for intermediate- or high-risk myelofibrosis, polycythemia vera, and graft-versus-host disease, offering an optimized once-daily dosing protocol.
• In January 2026, Takeda Pharmaceuticals and Protagonist Therapeutics submitted their New Drug Application to the U.S. FDA for rusfertide, supported by favorable 52-week data from the global Phase 3 VERIFY trial.
• According to DelveInsight, the United States contributed the largest prevalent population of Polycythemia Vera, accounting for ~55% of the 7MM in 2025, with the total number of prevalent cases in the US at around ~158,700 in 2025.
• In 2025, among current therapies for Polycythemia Vera, JAKAFI generated the largest revenue, at approximately USD 1,000 million in the United States.
• The Polycythemia Vera companies working in the space include Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, and Disc Medicine, among others.
• Promising Polycythemia Vera therapies such as Rusfertide, Bomedemstat, Givinostat (DUVYZAT), Sapablursen, Divesiran (SLN124), PPMX-T003, and 9MW3011/DISC-3405, among others.
Stay ahead in the Polycythemia Vera Therapeutics Market with DelveInsight's Strategic Report @ Polycythemia Vera Market Outlook-
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Polycythemia Vera Epidemiology Segmentation in the 7MM
• Total Prevalent Population of Polycythemia Vera
• Prevalent Population of Polycythemia Vera Based on Symptoms
• Gender-specific Prevalence of Polycythemia Vera
• Prevalence of Polycythemia Vera by Gene Mutation
• Prevalence of Polycythemia Vera Based on Risk
• Age-specific Prevalence of Polycythemia Vera
Download the report to understand which factors are driving Polycythemia Vera epidemiology trends @ Polycythemia Vera Prevalence-
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Polycythemia Vera Emerging Drugs
• Rusfertide (PTG-300): Protagonist Therapeutics and Takeda Pharmaceuticals
Rusfertide is a novel injectable synthetic mimetic of the natural hormone hepcidin, offering greater potency, solubility, and stability compared to the natural hormone, translating into improved pharmacokinetic and pharmacodynamic characteristics and manufacturability. Final results from the Phase II REVIVE trial, presented at ASH in December 2024, demonstrated that rusfertide, added to therapeutic phlebotomy with or without cytoreductive therapy, effectively controlled erythrocytosis, provided durable hematocrit control, and reduced the need for therapeutic phlebotomy. Protagonist Therapeutics filed an NDA for rusfertide in 2025, with an anticipated early launch in H2 2026, and the drug is currently in Phase III development.
• Sapablursen: Ionis Pharmaceutical/Ono Pharmaceutical (in partnership with Deciphera Pharmaceuticals)
Sapablursen is an investigational RNAi therapeutic that targets the TMPRSS6 gene to naturally elevate systemic hepcidin levels. Administered as a monthly subcutaneous injection, it aims to restore proper iron balance, suppress excess red blood cell production, and significantly decrease patients' weekly phlebotomy requirements. The global Phase 3 INTREPID trial began dosing its first patient in June 2026, and Ionis Pharmaceuticals has indicated plans to initiate a Phase III trial of sapablursen for Polycythemia Vera.
Polycythemia Vera Market Outlook
Polycythemia Vera treatment in the US is entering a new era with changing dynamics, though therapeutic options remain limited and no cure is currently available. The treatment landscape was historically dominated by legacy, generic therapies such as hydroxyurea, second-generation interferon, and phlebotomy, until the approval of BESREMi as both a first- and second-line treatment and JAKAFI in the second line only, with third-line options still limited. Low-dose aspirin and phlebotomy remain recommended first-line options for patients at low risk of thrombotic events, while cytoreductive therapy-usually hydroxyurea or interferon alpha-is recommended for high-risk patients. Treatment remains inadequate for many, as approximately 30% of hydroxyurea-treated patients become resistant or intolerant. The current market spans several therapeutic classes, including JAK inhibitors, interferons, hepcidin mimetics, TMPRSS6 inhibitors, CK1a inhibitors, BCL-2 inhibitors, and LSD1 inhibitors, with key players such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis Pharmaceuticals and Ono Pharmaceutical (sapablursen), Silence Therapeutics (Divesiran), Perseus Proteomics (PPMX-T003), and Disc Medicine (DISC-3405) advancing candidates through various stages of clinical development.
Get In-Depth Knowledge on Polycythemia Vera Market Trends and Forecasts with DelveInsight @ Polycythemia Vera Treatment Market-
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Scope of the Polycythemia Vera Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Polycythemia Vera Companies- Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, and others
• Polycythemia Vera Therapies- Ruxolitinib (JAKAFI/JAKAVI), Ropeginterferon alfa-2b (BESREMi), Rusfertide, Bomedemstat, Givinostat (DUVYZAT), Sapablursen (TMPRSS6), Divesiran (SLN124), PPMX-T003, 9MW3011/DISC-3405, and others
• Polycythemia Vera Therapeutic Assessment: Polycythemia Vera Current Marketed and Polycythemia Vera Emerging Therapies
• Polycythemia Vera Market Dynamics: Polycythemia Vera Market Drivers and Polycythemia Vera Market Barriers
Unlock Strategic Insights with DelveInsight's Comprehensive Polycythemia Vera Market Report @ Polycythemia Vera Market Drivers and Barriers-
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Polycythemia Vera Market Overview at a Glance
7. Disease Background and Overview
8. Treatment of Polycythemia Vera
9. Epidemiology and Patient Population of Polycythemia Vera
10. Patient Journey of Polycythemia Vera
11. Marketed Therapies
12. Emerging Drugs
13. Polycythemia Vera: 7MM Analysis
14. Unmet Needs of Polycythemia Vera
15. SWOT Analysis of Polycythemia Vera
16. KOL Views Polycythemia Vera
17. Market Access and Reimbursement of Polycythemia Vera
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polycythemia-vera-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycythemia Vera Market Size in the 7MM was ~USD 2,000 Million in 2025 and It is Expected to Grow at a Significant CAGR of 8.9% to Reach ~USD 5,600 Million by 2036, Estimates DelveInsight here
News-ID: 4579231 • Views: …
More Releases from DelveInsight Business Research LLP
Cognitive Impairment Associated with Schizophrenia Market Size was ~USD 948.1 Mi …
DelveInsight's "Cognitive Impairment Associated With Schizophrenia (CIAS) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CIAS, historical and forecasted epidemiology as well as the CIAS market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Cognitive Impairment Associated with Schizophrenia Market with DelveInsight's In-Depth Report @ CIAS Treatment Market-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the…
Acromegaly Pipeline Accelerates as 8+ Pharma Companies Rigorously Develop Drugs …
DelveInsight's "Acromegaly Pipeline Insight 2026" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acromegaly pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the…
Nephrotic Syndrome Pipeline Accelerates as 3+ Pharma Companies Rigorously Develo …
DelveInsight's "Nephrotic Syndrome Pipeline Insight 2026" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Nephrotic Syndrome pipeline landscape. It covers the Nephrotic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nephrotic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Chronic Lymphocytic Leukemia (CLL) Pipeline Insight 2026: 60+ Emerging Therapies …
DelveInsight's latest report, "Chronic Lymphocytic Leukemia (CLL) - Pipeline Insight, 2026," provides comprehensive insights into the evolving pipeline landscape, covering more than 55 companies and over 60 pipeline therapies across different stages of development.
The report offers a detailed evaluation of pipeline products, therapeutic approaches, clinical and non-clinical developments, mechanism of action analysis, licensing activities, mergers and acquisitions, collaborations, and regulatory designations shaping the future of the Chronic Lymphocytic Leukemia treatment…
More Releases for Polycythemia
Polycythemia Vera Market Massive Growth opportunity Ahead
Polycythemia Vera Market Outlook 2024-2034: Rising Diagnosis Rates and Advancements in Targeted Therapies to Drive Growth
Introduction
Polycythemia Vera (PV) is a rare chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, and in some cases, white blood cells and platelets. This leads to increased blood viscosity, higher risk of thrombosis, fatigue, headaches, and splenomegaly. PV is primarily associated with mutations in the JAK2 gene, which has shaped the…
Polycythemia Vera Pipeline: 10+ Therapies in Development by Pharma Giants Poised …
The Polycythemia Vera (PV) treatment landscape is undergoing significant evolution, driven by leading biopharmaceutical companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, and Perseus Proteomics. With JAK inhibitors like ruxolitinib already established, the focus has now shifted to next-generation therapeutics targeting disease-modifying mechanisms, cytokine signaling pathways, and novel erythropoiesis regulation. These therapies aim to reduce thrombotic risk, alleviate symptom burden, and delay progression to myelofibrosis.
DelveInsight's "Polycythemia Vera - Pipeline Insight,…
Polycythemia Clinical Trials, Drugs, Key Companies, Polycythemia Treatment Marke …
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight.
Polycythemia Overview:
Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period.
The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029).
Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.…
